UNITED STATES SECURITIES AND EXCHANGE COMMISSION

~~SECURITIES~~Washington, ~~AND~~D.C. ~~EXCHANGE COMMISSION~~20549

~~Washington D. C. 20549~~______________

FORM 8-K

~~CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934.~~______________

~~February~~CURRENT ~~1, 2008~~ REPORT

~~Date~~Pursuant ofto ~~Report~~Section 13 or 15(~~Date~~d) of ~~Earliest~~the ~~Event~~Securities ~~Reported)~~Exchange Act of 1934

~~DNAPrint~~Date ~~Genomics,~~of ~~Inc.~~Report (~~Exact~~Date ~~name~~ of ~~registrant~~earliest asevent ~~specified~~reported): January in25, ~~charter)~~2009

Utah		0-31905		59-2780520
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

^{______________}

~~1621~~DNAPrint ~~West University Parkway~~Genomics, ~~Sarasota, FL 34243 (Address of principal executive offices)~~Inc.

(~~941)~~Exact ~~366-3400~~name ~~(Registrant’s~~of ~~Telephone~~registrant ~~Number,~~as ~~including~~specified ~~Area~~in ~~Code~~its charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):______________

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Utah	0-31905	59-2780520
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

~~o Soliciting~~1621 ~~material~~West ~~pursuant~~University toParkway, ~~Rule~~Sarasota, ~~14a-12 under the Exchange Act (17 CFR 240.14a-12)~~FL 34243

~~o Pre-commencement~~ (Address ~~communications~~of ~~pursuant~~Principal toExecutive ~~Rule 14d-2(b~~Office) ~~under the Exchange Act~~ (17Zip ~~CFR 240.14d-2(b~~Code))

~~o Pre-commencement communications pursuant to Rule 13e-4~~ (c)Registrant’s ~~under~~telephone ~~the~~number, ~~Exchange~~including ~~Act~~area ~~(17 CFR 240.13e-4(c~~code))

~~ITEM 8.01~~N/A

~~OTHER~~(Former ~~EVENTS~~name or former address, if changed since last report)

OnCheck ~~January~~the ~~18,~~appropriate ~~2008,~~box ~~the~~below ~~Registrant~~if ~~entered~~the ~~into~~Form a8-K ~~nonbinding~~filing ~~letter~~is ofintended ~~intent~~to ~~with~~simultaneously ~~Nanobac~~satisfy ~~Pharmaceuticals,~~the ~~Incorporated~~filing ~~(“Nanobac”). This~~obligation ~~letter~~ of ~~intent~~the ~~was~~registrant ~~amended~~under onany ~~February 1, 2008. This letter~~ of ~~intent~~the ~~and~~following ~~amendment are filed with this 8-K.~~provisions:

~~ITEM~~¨ 9Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.01425)

~~EXHIBITS~~¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

~~99.01 Non~~¨ Pre-~~binding~~commencement ~~letter~~communications ofpursuant ~~intent~~to ~~dated~~Rule ~~January~~14d-2(b) ~~18,~~under ~~2008~~the ~~between~~Exchange ~~Nanobac~~Act ~~Pharmaceuticals,~~(17 ~~Incorporated~~CFR ~~and the Registrant~~240.14d-2(b))

~~99.02 Amendment~~¨ ~~dated~~Pre-commencement ~~February~~communications 1,pursuant ~~2008~~ to ~~the~~Rule ~~non~~13e-~~binding~~4(c) ~~letter~~under ofthe ~~intent~~Exchange ~~between~~Act ~~Nanobac~~(17 ~~Pharmaceuticals,~~CFR ~~Incorporate and the Registrant~~240.13e-4(c))

~~SIGNATURES~~Item 5.02

~~Pursuant~~Departure ~~to the requirements~~ of ~~the~~Directors ~~Securities~~or ~~Exchange~~Certain ~~Act~~Officers; Election of ~~1934,~~Directors; ~~the~~Appointment ~~Registrant~~of ~~has~~Certain ~~duly~~Officers; ~~caused~~Compensatory ~~this~~Arrangements ~~report~~of toCertain ~~be signed on its behalf by the undersigned, thereunto duly authorized~~Officers.

~~DNAPrint~~Employment ~~Genomics, Inc. By: /s/ Richard Gabriel Richard Gabriel Chief Executive Officer & President~~Termination

Effective as of January 25, 2009 Richard Gabriel, Chief Executive Officer and President and member of the board of directors resigns from all activities at DNAPrint Genomics, Inc. Ellipsis Biotherapeutics Corporation and Trace Genetics, Inc. and their respective boards of directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


	DNAPrint Genomics, Inc.


	By:	/s/ RICHARD GABRIEL
		Richard Gabriel Chief Executive Officer and President
		Richard Gabriel Chief Executive Officer and President

Date: February 9, 2009

Filing Compare · DNAPRINT GENOMICS INC